Site for Registry of Asthma Patients Initiating
Brief description of study
Site for Participant in this observational research study sponsored by Regeneron Pharmaceuticals, Inc., are being asked to participate because they are receiving treatment with dupilumab, since you are currently being treated for asthma by a study participating physician. The study is being done to characterize and collect long term data on patients 12 years and older with moderate to severe asthma, who receive treatment with dupilumab (also known as DUPIXENT®).
Clinical Study Identifier: s20-01492
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.